Study of Sunobinop on Alcohol Consumption in Alcohol Use Disorder

Phase 2

Recruiting

• Conditions: Alcohol Use Disorder
• Interventions: Drug: Placebo to match sunobinop; Drug: Sunobinop

• Registration Number: NCT06545916
• Lead Sponsor: Imbrium Therapeutics

Brief Summary

The purpose of this study is to evaluate the efficacy of sunobinop compared to placebo on alcohol consumption in subjects with alcohol use disorder.

Detailed Description

Not available

Study Timeline

• Study First Submitted: 2024-08-06
• Study First Submitted QC: 2024-08-06
• Study First Posted: 2024-08-09
• Study Start: 2024-10-14
• Status Verified: 2025-05
• Last Update Submitted: 2025-05-23
• Last Update Posted: 2025-05-25
• Primary Completion: 2025-07
• Study Completion: 2025-07

Recruitment & Eligibility

• Status: RECRUITING
• Sex: All
• Target Recruitment: 200

Inclusion Criteria

Not provided

Exclusion Criteria

Not provided

Study & Design

• Study Type: INTERVENTIONAL
• Study Design: PARALLEL

Arm && Interventions

Group	Intervention	Description
Placebo to match sunobinop	Placebo to match sunobinop	-
Sunobinop	Sunobinop	-

Primary Outcome Measures

Name	Time	Method
Percent heavy drinking days (HDD)	Day 57

Secondary Outcome Measures

Name	Time	Method
Number of standard unit drinks	Day 57
Percent of drinking days (PDD)	Day 57

Trial Locations

Locations (6)

Inquest Clinical Research; 🇺🇸 Baytown, Texas, United States

Bio Terra Med SRL; 🇷🇴 Bucharest, Romania

Spitalul Universitar De Urgenta Militar Central "Dr. Carol Davila"; 🇷🇴 Bucharest, Romania

Cabinet Medical Individual Dr. Andreea Popa; 🇷🇴 Bucharest, Romania

Belmont Medical Office; 🇺🇸 Brooklyn, New York, United States

Cebis Usa, Llc; 🇺🇸 Houston, Texas, United States